SCHEMBL19970843

SCHEMBL19970843

COC(=O)c1ccc(COc2ccccc2CN2CCN(C(=O)c3ccc4[nH]c(C(c5ccccc5)c5ccccc5)nc4c3)CC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.44
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 4/20 0.42
HTT P42858 2/20 0.42
MAPK14 Q16539 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
FAAH O00519 1/20 0.40
MGLL Q99685 1/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
TSHR P16473 2/20 0.39
CCR8 P51685 1/20 0.39
KCNH2 Q12809 1/20 0.39
MAPT P10636 1/20 0.39
USP2 O75604 2/20 0.39
MAPK1 P28482 1/20 0.39
GAA P10253 1/20 0.38
PKM P14618 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19970845 0.94 LMNA (0.44) LMNAALDH1A1KDM4EHTTMAPK14
SCHEMBL19970802 0.93 MEN1 (0.43) LMNAALDH1A1KDM4ESMN1; SMN2FAAH
SCHEMBL19970803 0.88 MEN1 (0.43) LMNAALDH1A1KDM4EFAAHMEN1
SCHEMBL19970844 0.87 LMNA (0.46) LMNAALDH1A1KDM4EHTTMAPK14
SCHEMBL19970731 0.84 ACACB (0.45) LMNAALDH1A1KDM4EHTTMAPK14
SCHEMBL19970795 0.82 ACACB (0.45) LMNAALDH1A1KDM4EHTTSMN1; SMN2
SCHEMBL19970846 0.81 MGLL (0.50) LMNAALDH1A1KDM4EHTTSMN1; SMN2
SCHEMBL23828686 0.79 LMNA (0.48) LMNAALDH1A1KDM4ESMN1; SMN2FAAH
SCHEMBL19970732 0.78 ACACB (0.52) LMNAALDH1A1KDM4EHTTSMN1; SMN2
SCHEMBL19970742 0.78 LSS (0.51) LMNAALDH1A1KDM4EHTTMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-10-25 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION FIP1L1, ZC3HAV1, MAVS LMNA 614/4885ALDH1A1 1822/4885KDM4E 1873/4885
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection FIP1L1, ZC3HAV1, MAVS LMNA 614/4885ALDH1A1 1822/4885KDM4E 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.